Ketoprofen transdermal - NAL Pharma
Alternative Names: NAL 1216Latest Information Update: 31 Oct 2021
Price :
$50 *
At a glance
- Originator NAL Pharma
- Class Analgesics; Antirheumatics; Nonsteroidal anti-inflammatories; Phenylpropionates; Small molecules
- Mechanism of Action Lipoxygenase-cyclooxygenase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Discontinued Pain
Most Recent Events
- 30 Aug 2016 Chemical structure information added
- 29 Aug 2016 Discontinued - Clinical-Phase-Unknown for Pain (Transdermal)
- 12 Aug 2016 Ketoprofen transdermal - NAL Pharma is available for licensing as of 12 Aug 2016. http://www.nalpharma.com/licensing.php?id=5&lang=en